{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Communications-Minutes-Decisions-Correspondence”
},
“headline”: “SOP for Ethics Committee and IRB Communications (Minutes, Decisions, Correspondence)”,
“description”: “This SOP outlines procedures for recording and managing Ethics Committee (EC) and Institutional Review Board (IRB) communications, including minutes, decisions, and correspondence, in compliance with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Communications (Minutes, Decisions, Correspondence)

Purpose

The purpose of this SOP is to establish standardized procedures for documenting and managing all communications with Ethics Committees (EC) and Institutional Review Boards (IRB), including meeting minutes, decisions, approval letters, and correspondence. This ensures transparency, accountability, and compliance with ICH GCP, WHO, FDA, EMA, and CDSCO requirements.

Scope

This SOP applies to all EC/IRB secretariat staff, investigators, sponsors, and regulatory personnel involved in preparing, distributing, and archiving EC/IRB communications for clinical trials. It covers routine communications, formal decisions, minutes of meetings, and correspondence with sponsors or investigators.

Responsibilities

• EC/IRB Chairperson: Ensures minutes accurately reflect deliberations and decisions.
• EC/IRB Secretariat: Prepares minutes, distributes decisions, and maintains correspondence logs.
• Investigators: Respond promptly to EC/IRB queries and implement required actions.
• Quality Assurance Officer: Reviews communication records for completeness and compliance.
• Head of Clinical Research: Oversees adherence to SOP and approves major communications if required.

Accountability

The EC/IRB Secretariat is accountable for ensuring accurate, timely, and secure documentation of all communications. Incomplete or inaccurate records may lead to regulatory non-compliance or invalidation of EC/IRB decisions.

Procedure

1. Preparation of Meeting Minutes
Secretariat drafts meeting minutes within 7 working days of EC/IRB meeting.
Minutes must include quorum details, list of attendees, protocol numbers reviewed, summary of discussions, and decisions taken.
Chairperson reviews and signs final version before distribution.

2. Recording Decisions
All EC/IRB decisions (approval, conditional approval, deferral, or disapproval) must be documented.
Decision letters must be issued to investigators and sponsors within 10 working days.
Copies must be filed in the EC/IRB Communication Log and Trial Master File (TMF).

3. Handling Correspondence
Secretariat maintains a log of all incoming and outgoing communications (letters, emails, faxes).
Each correspondence must include date, sender/receiver, subject, and reference number.
Critical correspondence must be acknowledged in writing.

4. Distribution of Communications
Copies of decisions, approvals, and minutes must be shared with investigators, sponsors, and regulatory authorities (if applicable).
Distribution must be documented in Communication Tracker.

5. Documentation and Archiving
All communications must be archived securely with restricted access.
Records must be retained for a minimum of 5 years after trial completion or longer if required by local regulations.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• TMF: Trial Master File
• QA: Quality Assurance

Documents

1. EC/IRB Meeting Minutes Template (Annexure-1)
2. Decision Letter Template (Annexure-2)
3. Communication Log (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA 21 CFR Part 56 – IRB Regulations
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, 2019

Version: 1.0

Approval Section

Annexures

Annexure-1: EC/IRB Meeting Minutes Template

Annexure-2: Decision Letter Template

Annexure-3: Communication Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Amendments-and-Notifications”
},
“headline”: “SOP for Ethics Committee and IRB Amendments and Notifications”,
“description”: “This SOP defines standardized procedures for submitting amendments and notifications to Ethics Committees and IRBs, ensuring compliance with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Amendments and Notifications

Purpose

The purpose of this SOP is to provide guidance on the preparation, submission, and follow-up of amendments and notifications to Ethics Committees (EC) and Institutional Review Boards (IRB). It ensures compliance with international (ICH GCP, WHO) and national (FDA, EMA, CDSCO) requirements for safeguarding trial participants and maintaining ethical oversight.

Scope

This SOP applies to sponsors, investigators, regulatory affairs staff, and quality assurance teams engaged in submitting protocol amendments, administrative changes, and safety-related notifications to EC/IRBs for clinical trials.

Responsibilities

• Principal Investigator (PI): Initiates protocol amendments and notifies EC/IRB of site-level changes.
• Regulatory Affairs Manager: Compiles and submits amendment packages and notifications to EC/IRBs.
• Clinical Research Associate (CRA): Ensures sites implement approved changes and maintains amendment records.
• Quality Assurance Officer: Reviews amendment documents for compliance before submission.
• Head of Clinical Research: Provides final approval before amendment submission.

Accountability

The Regulatory Affairs Head is accountable for ensuring that amendments and notifications are submitted promptly, accurately, and in accordance with regulatory requirements. Non-compliance may result in trial delays, ethical non-conformance, or regulatory findings.

Procedure

1. Identification of Amendment or Notification Requirement
Determine whether change qualifies as substantial (requiring EC/IRB approval) or non-substantial (requiring notification only).
Document reason for amendment or notification in Amendment Request Form.

2. Preparation of Amendment/Notification Package
Update trial documents such as protocol, informed consent forms, or recruitment materials.
Include cover letter, amendment description, justification, and impact analysis.
Compile supporting data (safety reports, investigator’s brochure updates, etc.).

3. Internal Review
QA verifies accuracy, completeness, and compliance with guidelines.
Head of Clinical Research approves final package.

4. Submission to EC/IRB
Submit amendment/notification electronically or in hard copy as per EC/IRB requirements.
Obtain acknowledgment of receipt.
Record submission details in Communication Log.

5. Follow-up and Approval Tracking
Track review and approval timelines in Amendment Tracker.
Respond promptly to EC/IRB queries.
File final approval letters in Trial Master File (TMF).

6. Implementation
Ensure approved changes are implemented at sites.
Provide training for site staff if amendments affect trial conduct.

Abbreviations

• SOP: Standard Operating Procedure
• EC: Ethics Committee
• IRB: Institutional Review Board
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. Amendment Request Form (Annexure-1)
2. Amendment Tracker (Annexure-2)
3. EC/IRB Communication Log (Annexure-3)

References

• ICH E6(R2) Good Clinical Practice
• US FDA 21 CFR Part 56 – IRB Requirements
• EMA Clinical Trial Regulation (EU No. 536/2014)
• WHO Guidelines for Ethics Committees
• CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Annexures

Annexure-1: Amendment Request Form

Annexure-2: Amendment Tracker

Annexure-3: EC/IRB Communication Log

Revision History

For more SOPs visit: Pharma SOP